FY2024 Earnings Forecast for Agenus Issued By William Blair

Agenus Inc. (NASDAQ:AGEN - Free Report) - William Blair raised their FY2024 earnings estimates for Agenus in a research note issued on Monday, January 27th. William Blair analyst M. Phipps now anticipates that the biotechnology company will post earnings per share of ($14.59) for the year, up from their prior forecast of ($15.34). The consensus estimate for Agenus' current full-year earnings is ($12.93) per share. William Blair also issued estimates for Agenus' Q4 2024 earnings at ($2.37) EPS, Q1 2025 earnings at ($1.31) EPS, Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.85) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($3.92) EPS, FY2026 earnings at ($2.91) EPS and FY2027 earnings at ($2.83) EPS.

Separately, HC Wainwright reiterated a "neutral" rating on shares of Agenus in a research report on Wednesday, January 22nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $10.00.

Agenus Trading Down 1.8 %

Shares of AGEN traded down $0.06 during mid-day trading on Thursday, hitting $3.55. The company's stock had a trading volume of 279,909 shares, compared to its average volume of 400,008. Agenus has a 1-year low of $2.50 and a 1-year high of $19.69. The firm has a market capitalization of $83.19 million, a P/E ratio of -0.32 and a beta of 1.27. The firm has a 50-day simple moving average of $3.23 and a 200 day simple moving average of $4.62.

Hedge Funds Weigh In On Agenus

Hedge funds have recently bought and sold shares of the company. Point72 DIFC Ltd purchased a new position in shares of Agenus in the second quarter valued at $51,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Agenus in the second quarter valued at approximately $106,000. HighTower Advisors LLC increased its stake in shares of Agenus by 46.1% during the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company's stock worth $122,000 after purchasing an additional 7,530 shares in the last quarter. Exchange Traded Concepts LLC raised its position in shares of Agenus by 52.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company's stock worth $151,000 after purchasing an additional 9,422 shares during the last quarter. Finally, State Street Corp lifted its stake in Agenus by 2.1% in the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company's stock valued at $2,563,000 after buying an additional 9,731 shares in the last quarter. 61.46% of the stock is owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.